Top Markets
Coin of the day
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Hisse Senetlerindeki Sıralama #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Hisse Fiyatı
$0.00001
Son senkronizasyon: 2026-09-10
Piyasa Değeri
$50.01K
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret MultiCell Technologies, Inc. (MCET)

Kategori

MultiCell Technologies, Inc. (MCET) için kazanç
Aug 2015 itibarıyla kazanç TTM: $-253.70
MultiCell Technologies, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-253.70'dir. 2013 yılında şirket $-1.37K kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
MultiCell Technologies, Inc. için kazanç geçmişi 2013 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $-253.70 -52.03%
2014 $-528.83 -61.38%
2013 $-1.37K 0.00%
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -2,079,155,336.02%
US
$1.95B -768,868,584.14%
NL
$-3.09B 1,216,772,201.58%
US
$-4.02B 1,583,024,389.96%
AU
- -
CH